SPONSOR
Chiesi Farmaceutici S.p.A.
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 3
Chiesi Farmaceutici S.p.A. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Alpha-Mannosidosis, Fabry Disease, Pregnancy, Pregnancy Complications.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chiesi Farmaceutici S.p.A.
How many clinical trials has Chiesi Farmaceutici S.p.A. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Chiesi Farmaceutici S.p.A., of which 3 are actively recruiting participants. These trials cover conditions including Alpha-Mannosidosis, Fabry Disease, Pregnancy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chiesi Farmaceutici S.p.A. research focus on?
Chiesi Farmaceutici S.p.A. clinical trials span Alpha-Mannosidosis, Fabry Disease, Pregnancy, Pregnancy Complications. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chiesi Farmaceutici S.p.A. clinical trial?
To participate in a Chiesi Farmaceutici S.p.A. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chiesi Farmaceutici S.p.A. trials with current recruitment status updated daily.
Clinical Trials by Chiesi Farmaceutici S.p.A.
NCT06184503
Recruiting
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
Alpha-Mannosidosis
NCT06941025
Recruiting
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Fabry Disease
NCT06328608 Phase 2, Phase 3
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Fabry Disease
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology